On February 25, 2026, Charles River Laboratories announced it will divest its CDMO and Cell Solutions businesses for performance-based payments totaling approximately $143 million in annual revenue and sell European Discovery Services assets for $145 million cash. These divestitures are expected to decrease 2026 reported revenue by over $200 million but improve operating margins and earnings per share by approximately $0.10.